<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Parkinsons Dis</journal-id><journal-title-group><journal-title>NPJ Parkinson's Disease</journal-title></journal-title-group><issn pub-type="epub">2373-8057</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6851126</article-id><article-id pub-id-type="publisher-id">95</article-id><article-id pub-id-type="doi">10.1038/s41531-019-0095-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let&#x02019;s talk about the lipids in the room</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Killinger</surname><given-names>Bryan A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Melki</surname><given-names>Ronald</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Brundin</surname><given-names>Patrik</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kordower</surname><given-names>Jeffrey H.</given-names></name><address><phone>+312-563-3585</phone><email>Jeffrey_Kordower@rush.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution>Department of Neurological Sciences, </institution><institution>Rush University Medical Center, </institution></institution-wrap>Chicago, IL 60612 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2112 9282</institution-id><institution-id institution-id-type="GRID">grid.4444.0</institution-id><institution>CEA and Laboratory of Neurodegenerative Diseases, </institution><institution>Institut Francois Jacob (MIRCen), CNRS, </institution></institution-wrap>92265 Fontenay-Aux-Roses cedex, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0406 2057</institution-id><institution-id institution-id-type="GRID">grid.251017.0</institution-id><institution>Center for Neurodegenerative Science, </institution><institution>Van Andel Research Institute, </institution></institution-wrap>Grand Rapids, MI 49503 USA </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>5</volume><elocation-id>23</elocation-id><history><date date-type="received"><day>23</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>9</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Alpha-synuclein is an intrinsically disordered, highly dynamic protein that pathogenically aggregates into inclusion structures called Lewy bodies, in several neurogenerative diseases termed synucleinopathies. Despite its importance for understanding disease, the oligomerization status of alpha-synuclein in healthy cells remains unclear. Alpha-synuclein may exist predominantly as either a monomer or a variety of oligomers of different molecular weights. There is solid evidence to support both theories. Detection of apparent endogenous oligomers are intimately dependent on vesicle and lipid interactions. Here we consider the possibility that apparent endogenous alpha-synuclein oligomers are in fact conformations of membrane-bound alpha-synuclein and not a bona fide stable soluble species. This perspective posits that the formation of any alpha-synuclein oligomers within the cell is likely toxic and interconversion between monomer and oligomer is tightly controlled. This differs from the hypothesis that there is a continuum of endogenous non-toxic oligomers and they convert, through unclear mechanisms, to toxic oligomers. The distinction is important, because it clarifies the biological origin of synucleinopathy. We suggest that a monomer-only, lipid-centric view of endogenous alpha-synuclein aggregation can explain how alpha-synuclein pathology is triggered, and that the interactions between alpha-synuclein and lipids can represent a target for therapeutic intervention. This discussion is well-timed due to recent studies that show lipids are a significant component of Lewy pathology.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Neuroscience</kwd><kwd>Molecular biology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Alpha-synuclein (&#x003b1;Syn) is an intrinsically disordered, highly flexible protein, which plays an important role in the pathogenesis of several neurodegenerative diseases cumulatively referred to as synucleinopathies. In different synucleinopathies, neurons and/or glia bare the hallmark intracellular deposits of filamentous &#x003b1;syn<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> but the origin of this pathology remains unclear. &#x003b1;Syn oligomers with &#x003b2;-sheet structure (&#x003b1;synO-&#x003b2;) are toxic to cells, possibly through physical disruption of cellular membranes.<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup> &#x003b1;SynO-&#x003b2;/preformed fibrils (PFFs) generated in vitro or isolated from the brains of patients developing synucleinopathies can &#x0201c;seed&#x0201d; aggregates, especially in transgenic rodent models overexpressing &#x003b1;syn,<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> and initiate a toxic cascade reminiscent of that seen in disease.<sup><xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref></sup> However, not all oligomers are believed to be bad actors, as evidence suggests that various oligomers may not only exist in the cell but also have normal cellular functions.<sup><xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref></sup> Indeed, some conformers of &#x003b1;synO-&#x003b2; do not seed pathology and are non-toxic.<sup><xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref></sup> Functional endogenous oligomers have been controversial, as their existence has been both confirmed and refuted by carefully executed studies.<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup></p><p id="Par3">Are there benign &#x003b1;syn oligomers that have normal cellular functions, and if so, how do they transition to toxic &#x003b1;synO-&#x003b2;? Here, in this short review, we discuss how lipid&#x02013;&#x003b1;syn interactions might help explain the observation of apparent endogenous non-toxic oligomers and highlight alternative models that are monomer-centric. Furthermore, we will extend this viewpoint to consider its implications for synucleinopathy pathogenesis. There has been substantial work done in this area and several exhaustive reviews on lipid&#x02013;&#x003b1;syn interactions<sup><xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref></sup> and oligomerization<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup> are available; hence, for the sake of clarity, we will not comprehensively discuss the literature.</p></sec><sec id="Sec2"><title>Biology of lipids in neurodegenerative disease</title><p id="Par4">The brain is ~60% lipids by weight.<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> Lipids have diverse cellular functions in biology including cell signaling, energy storage, and structural partitioning.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> Phospholipids contain amphipathic characteristics with a charged hydrophilic phosphate group and a carbon chain of varying lengths.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> Phospholipids spontaneously form bilayer structures in aqueous solutions that are the basis of cellular membranes. Lipids have not been as extensively studied as proteins in vivo, possibly because of their hydrophobicity, chemical complexity, and the fact that they are not gene products.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> However, lipids are crucial for cellular function and are implicated in several neurodegenerative diseases including synulceinopathies.<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> Recent technological advances with lipodomic analysis have furthered the study of lipids.<sup><xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref></sup> Current lipodomic analyses, however, are focused on whole-cell lysates and therefore insensitive to cellular spatial and temporal dimensions, which are crucial for understanding lipid function.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup></p></sec><sec id="Sec3"><title>&#x003b1;Syn&#x02013;vesicle membrane interactions</title><p id="Par5">Shortly following the discovery of &#x003b1;syn in Lewy pathology,<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> the lipid-binding properties of asyn were documented and the significance of disease-causing point mutations in lipid-binding domains was recognized.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> Indeed, one of the earliest histochemical descriptions of Lewy bodies noted that they stain positively for phospholipids, particularly sphingomyelin.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> Since then, interactions between &#x003b1;syn and vesicle lipids have been implicated in the initial generation of synucleinopathy.<sup><xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref></sup> The hypothesis that lipids control pathological &#x003b1;syn aggregation primarily stems from observations that lipids/vesicles influence aggregation kinetics in vitro,<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref></sup> and that disease-related missense mutations of <italic>SNCA</italic> alter residues within the N-terminal lipid-binding domain of &#x003b1;syn.<sup><xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref></sup> &#x003b1;Syn may redistribute to lipid compartments early in disease pathogenesis.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> Several disease-causing &#x003b1;syn mutants abnormally associate with intracellular vesicles and lipid droplets,<sup><xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup> and dyshomeostasis of intracellular lipids are likely an early molecular event preceding pathology formation.<sup><xref ref-type="bibr" rid="CR49">49</xref></sup> The key to pathogenesis lies within the lipid-binding domain of &#x003b1;syn.</p><p id="Par6">&#x003b1;Syn binding to vesicular membranes is important, because it influences oligomerization and pathological aggregation. Evidence suggests that non-pathological &#x003b1;syn is involved with vesicular dynamics in cells<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR55">55</xref></sup> and regulation of the presynaptic vesicle pool.<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup> &#x003b1;Syn&#x02013;lipid interactions may have a vesicle tethering function. It has been proposed that the broken &#x003b1;-helical N-terminus can function to tether intracellular vesicles via a &#x0201c;double-anchor&#x0201d; mechanism.<sup><xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref></sup> The biological significance of &#x003b1;syn-mediated clustering is unknown; however, it could serve to promote the exchange of lipids between adjacent vesicles<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> and possibly promote vesicle fusion.<sup><xref ref-type="bibr" rid="CR56">56</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref></sup> &#x003b1;Syn preferentially binds to membranes with lipid-packing defects<sup><xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR68">68</xref></sup> and high curvature.<sup><xref ref-type="bibr" rid="CR69">69</xref>&#x02013;<xref ref-type="bibr" rid="CR72">72</xref></sup> In the neurons, &#x003b1;syn is densely clustered around intracellular vesicles and vesicular tubule structures, most prominently at the nerve terminal.<sup><xref ref-type="bibr" rid="CR73">73</xref></sup> When incubated with small (~10&#x02013;30&#x02009;nm) unilamaller vesicles, the N-terminal of &#x003b1;syn adopts an extended &#x003b1;-helical conformation as it coats the vesicular surface and a broken &#x003b1;-helical conformation when interacting with micelles.<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR74">74</xref>&#x02013;<xref ref-type="bibr" rid="CR80">80</xref></sup> The interaction between the N-terminus of &#x003b1;syn with lipid membranes is driven by electrostatic interactions between positively charged residues and lipid phosphate head group.<sup><xref ref-type="bibr" rid="CR81">81</xref></sup> When membrane bound, the N-terminus residues (1&#x02013;26) of &#x003b1;syn rigidly bind to the membrane and the internal segment (residues 26&#x02013;97) acts to sense lipid properties and regulates binding affinity.<sup><xref ref-type="bibr" rid="CR82">82</xref></sup> Interestingly, the hydrophobic stretch of residues 71&#x02013;82 are required for pathological aggregation of &#x003b1;syn<sup><xref ref-type="bibr" rid="CR83">83</xref></sup> and, therefore, lipid-sensing properties of &#x003b1;syn and pathological aggregation occur through the same functional domain. It is not clear whether mutation of the N-terminus results in a toxic gain of function or loss of function.</p><p id="Par7">Many cellular functions have been attributed to &#x003b1;syn and membrane interactions, including soluble N&#x02010;ethylmaleimide sensitive factor attachment protein receptor (SNARE) complex assembly and exocytosis; however, the exact cellular function of &#x003b1;syn remains unclear.<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR84">84</xref></sup> &#x003b1;Syn interacts with SNARE proteins at the vesicle surface.<sup><xref ref-type="bibr" rid="CR85">85</xref>&#x02013;<xref ref-type="bibr" rid="CR88">88</xref></sup> &#x003b1;Syn binding to membranes promotes SNARE complex formation and may function as a SNARE chaperone protein.<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR88">88</xref>,<xref ref-type="bibr" rid="CR89">89</xref></sup> Vesicular membrane-binding promotes the oligomerization of &#x003b1;syn.<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> In vitro phospholipids can also increase the rate of pathological aggregation (i.e., &#x003b2;-sheet confirmations) by decreasing lag time of primary nucleation.<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup> The effect of lipids on &#x003b1;syn aggregation is dependent on lipid to protein ratio, with a low ratio promoting aggregation and higher ratio being inhibitory.<sup><xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR91">91</xref></sup> This bimodal phenomenon probably results from a lack of monomer available for oligomer elongation when the lipid ratio is too high. Interestingly, increasing &#x003b1;syn expression, presumably shifting the intracellular lipid to protein ratio, promotes aggregation of &#x003b1;syn in cells. Notably, it has been hypothesized that reducing monomeric &#x003b1;syn is an important therapeutic target.<sup><xref ref-type="bibr" rid="CR92">92</xref>&#x02013;<xref ref-type="bibr" rid="CR94">94</xref></sup></p><p id="Par8">A confusing aspect to the literature is that binding of &#x003b1;syn to membranes has been reported to both inhibit<sup><xref ref-type="bibr" rid="CR95">95</xref>&#x02013;<xref ref-type="bibr" rid="CR97">97</xref></sup> and to promote &#x003b1;syn aggregation.<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup> This may be due to differences in assay conditions between studies, such as membrane lipid composition and &#x003b1;syn concentration. Indeed, recent studies using lipodomics implicated specific fatty acid oleic acid in the pathogenesis of Parkinson&#x02019;s disease.<sup><xref ref-type="bibr" rid="CR49">49</xref></sup> In the model proposed by Fanning and colleagues<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>, soluble &#x003b1;syn binds to oleic acid, effectively sequestering the monomer to lipid membranes and ultimately culminating in pathological aggregate formation. As they also observed an increase in oleic acid in response to &#x003b1;syn overexpression, there may be a toxic lipid dyshomeostatis that preceeds aggregate formation. Their results suggest a complex origin of synucleinopathy where both lipid metabolism and &#x003b1;syn are central players.</p><p id="Par9">&#x003b1;Syn may have a more generalized cellular function as an effector of lipid dynamics, and not as a factor of a specific subprocess or pathway. To highlight this concept, consider the curious relationship between &#x003b1;syn and erythropoiesis (i.e., red blood cell differentiation) for which others have hypothesized &#x003b1;syn that may have an underlying redundant mechanism in the two cells of different linage.<sup><xref ref-type="bibr" rid="CR98">98</xref></sup> &#x003b1;Syn is highly expressed in erythrocytes under the control of transcription factor GATA1.<sup><xref ref-type="bibr" rid="CR99">99</xref>,<xref ref-type="bibr" rid="CR100">100</xref></sup> During the terminal step of erythropoiesis, &#x003b1;-syn expression dramatically increases and remains elevated in the mature erythrocyte.<sup><xref ref-type="bibr" rid="CR98">98</xref></sup> &#x003b1;Syn is then found associated with phospholipids and vesicle membranes in the mature erythrocyte.<sup><xref ref-type="bibr" rid="CR101">101</xref></sup> Thus, which of the proposed cellular functions does &#x003b1;syn perform during erythropoiesis? One likely explanation is that &#x003b1;syn plays a role in the dramatic intracellular lipid organization, analogous to asymmetric cytokinesis, which occurs prior to the phenomenon of enucleation. Enucleation is the process by which organelles are condensed and extruded from the cell to form a mature erythrocyte. Indeed, just prior to enucleation &#x003b1;syn can be found associated with lipids of the cell, particularly the nucleus and ER, which are key players in enucleation. &#x003b1;Syn accumulates at the site of nuclear extrusion,<sup><xref ref-type="bibr" rid="CR102">102</xref></sup> suggesting it is directly involved with enucleation lipid dynamics. Concurrently, SNARE machinery is decreased in the erythrocyte, suggesting that the potential involvement of &#x003b1;syn in lipid dynamics during enucleation is independent of hypothesized SNARE functions.<sup><xref ref-type="bibr" rid="CR103">103</xref></sup> However, if &#x003b1;syn is involved in this cellular phenomenon, it is non-essential or interchangeable with beta or gamma synucleins, as only minor phenotypic abnormalities of erythrocytes are observed in &#x003b1;-syn-knockout models.<sup><xref ref-type="bibr" rid="CR99">99</xref></sup></p></sec><sec id="Sec4"><title>Soluble oligomers devoid of lipid</title><p id="Par10">There is good evidence of a naturally occurring metastable soluble &#x003b1;syn oligomer (i.e., tetramer) that is devoid of vesicle/lipid binding.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> However, the existence of a soluble &#x003b1;syn tetramer is based mostly on results from crosslinking experiments.<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR104">104</xref>&#x02013;<xref ref-type="bibr" rid="CR106">106</xref></sup> The interpretation of crosslinking experiments is non-trivial. &#x003b1;Syn tetramers are captured when using a permissive chemical cross-linker with spacer arm length (DSG spacer arm length 7.7&#x02009;&#x000c5;) and perhaps not with a shorter spacer arm (formalin spacer arm length ~2&#x02009;&#x000c5;).<sup><xref ref-type="bibr" rid="CR107">107</xref></sup> A milieu of progressively larger oligomers are formed and captured even when purified recombinant &#x003b1;syn is incubated with glutaraldehyde.<sup><xref ref-type="bibr" rid="CR108">108</xref></sup> The successful detection of an &#x003b1;syn tetramer in tissues and cells is dependent on sample preparation conditions and can be detected when cells remain intact prior to crosslinking or when tissue lysates are kept highly concentrated.<sup><xref ref-type="bibr" rid="CR107">107</xref></sup> Indeed, purification of &#x003b1;syn prevents the detection of a soluble tetramer further suggesting a cofactor is required and this factor is likely of lipid origin.<sup><xref ref-type="bibr" rid="CR109">109</xref></sup> Although the question remains which lipid cofactor might be responsible for the tetramer formation, the tetramer and &#x003b1;syn&#x02013;lipid interactions are inextricably linked. This is highlighted when recently a transgenic mouse model (called &#x0201c;3K&#x0201d;) of tetramer deficiency was generated by introducing 3E&#x02013;&#x02009;&#x0003e;&#x02009;K mutations in &#x003b1;syn&#x02019;s lipid-binding N-terminus.<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> These 3K mice exhibit aggressive &#x003b1;syn aggregation, loss of an apparent tetramer, and a motor phenotype that has some semblance to Parkinson&#x02019;s disease. The lipid-binding domain was mutated in the 3K mice and correspondingly lipid interactions were enhanced<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> and similar to what was observed with similar mutations in cells.<sup><xref ref-type="bibr" rid="CR110">110</xref></sup> In both mice and cells, mutated 3K &#x003b1;syn clustered around vesicles and intact tissue crosslinking captured less soluble tetramer.<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR106">106</xref>,<xref ref-type="bibr" rid="CR110">110</xref></sup> Was this due to less tetramer or alternatively less soluble tetramer? The results could be explained either way, but if the captured &#x003b1;syn species is truly an insoluble tetramer, one would expect less detection in the soluble fraction, as the authors observed. Indeed, the results appear to fit a scenario where folding on the vesicular membrane is driving &#x003b1;syn pathology without the need for a soluble tetramer. (Fig. <xref rid="Fig1" ref-type="fig">1</xref>)<fig id="Fig1"><label>Fig. 1</label><caption><p>Endogenous soluble oligomers are inextricably associated with lipid/vesicle binding. Depicted is an possible explanation for the detection of a soluble &#x003b1;syn oligomer. In the cytoplasm, &#x003b1;syn exists in an equilibrium between a disordered slightly compact monomer and membrane-bound &#x003b1;-helix confirmation. The N-terminus of &#x003b1;syn binds to vesicle membranes via electrostatic interactions and adopts an &#x003b1;-helix structure. &#x003b1;Syn most likely binds to localized areas of vesicle surfaces with lipid-packing defects. Normally, in the cell ~5&#x02013;10% of &#x003b1;syn is interacting with vesicle surfaces. The same percentage is also proposed for soluble oligomers. Covalent bonds between adjacent &#x003b1;syn molecules capture the confirmations bound to the vesicle surface. Covalent modification of amino-acid residue side chains, especially lysine, following chemical crosslinking neutralizes a portion of &#x003b1;syn charge required for membrane binding. The captured species could then retain the membrane-bound confirmation and enter the aqueous phase for subsequent detection. Thus, endogenous soluble functional oligomers are unlikely, in agreement with several studies. Instead, endogenous oligomers may represent confirmations of membrane-bound &#x003b1;syn. This hypothesis makes lipid-syn interactions at the membrane a crucial mediator of pathology initiation. DSP dithiobis(succinimidyl propionate), DSG disuccinimidyl glutarate</p></caption><graphic xlink:href="41531_2019_95_Fig1_HTML" id="d29e674"/></fig></p><p id="Par11">Detection of endogenous oligomers, including the tetramer, could be explained by compartmentalized &#x003b1;syn residing on the vesical membrane (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Membrane interactions occur through electrostatic forces between positively charged lysine residues of &#x003b1;syn and negatively charge phosphate group of lipids.<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR81">81</xref>,<xref ref-type="bibr" rid="CR111">111</xref></sup> Interestingly, the same crosslinking chemicals used to capture tetramers chemically modify lysine side chains of &#x003b1;syn and neutralize their charge.<sup><xref ref-type="bibr" rid="CR112">112</xref></sup> Chemically modifying the lysine side chains during tissue crosslinking would presumably disrupt membrane binding, because it neutralizes the required electrostatic charge of lysine residues. Therefore, captured oligomers would dissociate from the membrane and would be detected in the soluble fraction, producing the characteristic gel-shift of the &#x003b1;syn tetramer.<sup><xref ref-type="bibr" rid="CR106">106</xref></sup> To highlight this concept, the neutralization of &#x003b1;syn charge by chemical cross-linkers is routinely used to enhance the retention of &#x003b1;syn on polyvinylidene difluoride membranes during western blotting protocols.<sup><xref ref-type="bibr" rid="CR112">112</xref></sup> Together, adjacent &#x003b1;syn molecules bound to intracellular vesicle surfaces (i.e., compartmentalized) might disassociate into the soluble fraction once chemically modified by the crosslinking reagent. This phenomenon would also help explain why the soluble tetramer has similar intermolecular n-terminal structure as the membrane-bound form.</p><p id="Par12">The apparent soluble tetramer may be stabilized by covalent bonds formed in the oxidative environment of the erythrocyte (i.e., the source from which it was originally isolated). Biochemical characterization of a putative &#x003b1;syn tetramer was mostly done using erythrocyte derived &#x003b1;syn.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> Erythrocytes have millimolar concentrations of hemoglobin. Hemoglobin oxidatively catalyzes the formation of intramolecular dityrosine bonds resulting in a mixture of &#x003b1;syn dimers and tetramers.<sup><xref ref-type="bibr" rid="CR113">113</xref></sup> Dityrosine crosslink formation occurs rapidly<sup><xref ref-type="bibr" rid="CR113">113</xref>,<xref ref-type="bibr" rid="CR114">114</xref></sup> and would likely occur to some extent during &#x003b1;syn purification from erythrocytes. &#x003b1;Syn in erythrocytes associates with vesicles<sup><xref ref-type="bibr" rid="CR101">101</xref>,<xref ref-type="bibr" rid="CR102">102</xref></sup> and stable dityrosine &#x003b1;syn occurs in clinical blood samples.<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> Together, it is probable that stable &#x003b1;syn oligomers isolated from erythrocytes are due to oxidative crosslinking of adjacent &#x003b1;syn molecules bound to vesicle membranes. Heat denaturation irreversibly abolished the tetramers &#x003b1;-helix structure, indicating that the captured configuration was not in equilibrium but instead was a stabilized structure originating from the tissue (i.e., vesicle bound). Lipid binding of the tetramer was enhanced when compared with the monomer, further suggesting it retained a lipid-binding confirmation.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> Removal of lipids with Lipodex 1000 did not affect the tetramer detection, suggesting the tetramer was not associated with any stabilizing lipid structure. Stabilization of small oligomers via oxidative crosslinking can prevent progressive aggregation and might explain why the stable tetramer appears to resist aggregation.<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR116">116</xref></sup> Together, it is likely to be that the stable soluble &#x003b1;syn tetramer purified from erythrocyte is a covalently stabilized membrane-bound confirmation similar to that captured using exogenous crosslinking agents.</p><p id="Par13">Soluble &#x003b1;syn oligomers have been detected using several imaging techniques. F&#x000f6;rster resonance energy transfer (FRET) is a powerful technique used to determine intermolecular distances between molecules with 1&#x02013;2&#x02009;nm spatial resolution.<sup><xref ref-type="bibr" rid="CR117">117</xref></sup> FRET has been employed to study various aspects of &#x003b1;syn oligomerization mostly in vitro<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR118">118</xref>&#x02013;<xref ref-type="bibr" rid="CR120">120</xref></sup> but also ex vivo<sup><xref ref-type="bibr" rid="CR121">121</xref></sup> and in vivo.<sup><xref ref-type="bibr" rid="CR122">122</xref></sup> In vitro, purified &#x003b1;syn forms distinct oligomer conformers, which then can spontaneously convert to protease resistant and toxic &#x003b1;synO-&#x003b2;.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> Biomolecular fluorescence complementation (BiFC) technique uses fluorescent constructs to determine protein&#x02013;protein interaction. BiFC constructs have been used to study &#x003b1;syn aggregation in vivo;<sup><xref ref-type="bibr" rid="CR123">123</xref>,<xref ref-type="bibr" rid="CR124">124</xref></sup> however, the resolution of this technique cannot differentiate between small oligomers and complex formation (i.e., membrane bound). The method detects diffuse staining in neurons lacking pathology, suggesting either small aggregates or close association of &#x003b1;syn molecules normally within the cytosol.<sup><xref ref-type="bibr" rid="CR124">124</xref></sup> &#x003b1;Syn comes into close proximity around synaptic vesicles and possibly forms multimers on the membrane.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> Other BiFC techniques employing photoactivatable fluorescent molecules can increase the spatial resolution to several nanometers,<sup><xref ref-type="bibr" rid="CR125">125</xref></sup> but this type of imaging has yet to be done with &#x003b1;syn.</p></sec><sec id="Sec5"><title>Soluble disordered monomer devoid of lipid</title><p id="Par14">There is also good evidence that &#x003b1;syn exists predominantly as an intrinsically disordered monomer in the cytosol.<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR126">126</xref>&#x02013;<xref ref-type="bibr" rid="CR130">130</xref></sup> &#x003b1;Syn purified from <italic>Escherichia coli</italic> behaves as an intrinsically disordered protein with a large stokes radius,<sup><xref ref-type="bibr" rid="CR129">129</xref></sup> which may be why monomeric &#x003b1;syn appears to have greater mass in some assays.<sup><xref ref-type="bibr" rid="CR126">126</xref></sup> Non-denaturing purification procedures from several tissue sources also produce a disordered monomeric &#x003b1;syn.<sup><xref ref-type="bibr" rid="CR126">126</xref></sup> A disordered soluble monomer has been observed directly using in-cell nuclear magnetic resonance (NMR) imaging techniques.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> Specifically, investigators transfected cells with recombinant &#x003b1;syn labeled with <sup>15</sup>N isotope to monitor individual &#x003b1;syn molecules within the living cells. Results showed that the majority of monomeric &#x003b1;syn maintained a disordered confirmation in the cell, while becoming slightly more compact than in free solution, probably due to molecular crowding.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> The compact structure observed in vivo likely prevents spontaneous aggregation in the cytosol.<sup><xref ref-type="bibr" rid="CR131">131</xref></sup> Although this is compelling evidence that the majority of &#x003b1;syn in the cell occurs as a disordered monomer, the result does not rule out the existence of a tetramer. A tetramer that existed at low concentration would not be detected and it is possible that the recombinant &#x003b1;syn behaved dissimilarly to endogenous &#x003b1;syn. Importantly, this study demonstrated that the majority of &#x003b1;syn in the cell is cytosolic and monomeric, and suggests that membrane interactions are likely transient and highly dependent on local environment (e.g., nerve terminal). Correspondingly, it would be interesting if &#x003b1;syn persists as a monomer at axon terminals where it&#x02019;s vesicle interactions are more prominent than in the cell body.<sup><xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR132">132</xref></sup> The &#x003b1;-helix conformation &#x003b1;syn was recently described in HELA cells using FRET, where it was demonstrated that &#x003b1;syn assumes several confirmations when interacting with vesicle surfaces.<sup><xref ref-type="bibr" rid="CR133">133</xref></sup> Considered together, the majority of &#x003b1;syn in the cell exists as a relatively compact disordered monomer and adopts an &#x003b1;-helix structure when interacting with vesicle membranes. The native state of &#x003b1;syn may not include an oligomer, whether free and soluble, or vesicle bound.</p></sec><sec id="Sec6"><title>Aberrant vesicle binding progresses to pathology</title><p id="Par15">Assuming monomeric &#x003b1;syn is interacting with vesicle membranes, and remains monomeric at the vesicle surface under normal circumstances, how might pathology begin? (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). One possible scenario involves vesicle surfaces acting as two-dimensional (2D) reactors that promote pathogenic intermolecular interactions of &#x003b1;syn.<sup><xref ref-type="bibr" rid="CR91">91</xref>,<xref ref-type="bibr" rid="CR134">134</xref>&#x02013;<xref ref-type="bibr" rid="CR136">136</xref></sup> In the cystosol, &#x003b1;syn remains monomeric and in a slightly compact configuration. Transient interactions with vesicle surfaces induce a conformational shift, but not necessarily oligomerization, and concentrate &#x003b1;syn molecules on the vesicle surface. This focal point on the vesicle surface is where opposing &#x003b1;syn molecules bind and might serve as the molecular origins for Lewy pathology. Numerous cellular and genetic factors converge at this focal point in such a way that creates an environment conducive for the initiation of pathogenic &#x003b1;syn aggregation. Studies using sonicated &#x003b1;syn PFFs suggest that once the &#x003b1;synO-&#x003b2; is present, progressive aggregation and toxicity follow.<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR137">137</xref></sup> Yet, studies that utilize PFF&#x02019;s to assess pathology are bypassing pathology generation and may be recapitulating downstream pathological events. Therefore, the use of PFF&#x02019;s to study synucleinopathy is likely to give valuable insight into the progression of these diseases and perhaps are not suitable to study the initiation of the disease.<fig id="Fig2"><label>Fig. 2</label><caption><p>Potential role of lipids in &#x003b1;syn aggregate pathoetiology. In the cell, &#x003b1;syn is partitioned between aqueous phase and the lipid phase via transient interactions at the vesicle surface. Endogenous &#x003b1;syn probably exists in several states, including a compact monomer and a vesicle-bound monomer with an N-terminal &#x003b1;-helix structure. Folding &#x003b1;syn monomers on the vesicle surfaces likely plays a non-essential or redundant role in vesicle dynamics. &#x003b2;-Sheet confirmation of &#x003b1;syn may begin at vesicle surfaces. Toxic effects of &#x003b2;-sheet oligomers included vesicle permeabilization or the formation of toxic mixed lipid&#x02013;protein structures. Pathology initiation might involve specific configurations of &#x003b1;syn folding onto a variety of membranes. Altered lipid-sensing properties by known disease-causing mutations (e.g., A30P, E46K, and A53T) might alter the affinity of &#x003b1;syn for certain vesicle lipid components (depicted as yellow and red circles), or change the spatial arrangement of &#x003b1;syn molecules on the vesicle surface. Resulting &#x003b2;-sheet oligomers may have different toxic or prion-like properties based the physiochemical details of the initial pathology development</p></caption><graphic xlink:href="41531_2019_95_Fig2_HTML" id="d29e889"/></fig></p><p id="Par16">At the membrane, &#x003b1;synO-&#x003b2; might act similar to a &#x0201c;molecular shovel&#x0201d; inserting itself into the membrane with destructive, toxic, consequences.<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR138">138</xref></sup> Together with lipid/vesicle interactions at the center of &#x003b1;syn function, a route to pathophysiology might be the collapse of clustered lipids/vesicles into a pathological inclusion. Similar to a massive star transitioning to a black hole, at some point pathological &#x003b1;syn and lipids form a critically dense structure, and compact to form a Lewy body. Interestingly, the architecture of the Lewy pathology supports this interpretation.<sup><xref ref-type="bibr" rid="CR139">139</xref>&#x02013;<xref ref-type="bibr" rid="CR144">144</xref></sup> Neuropathological examination of patient brains shows a mixture of &#x003b1;syn staining in neurons that consist of a pale diffuse, punctate irregular shape (i.e., uneven distribution), discrete body (i.e., pale body), and a massive dense structure with a pale core (i.e., Lewy body).<sup><xref ref-type="bibr" rid="CR139">139</xref></sup> These structures have been hypothesized to be snapshots of a pathological process with Lewy bodies being the result. Indeed, pale bodies contain a mixture of granular and vesicular structures and are often found near mature LB.<sup><xref ref-type="bibr" rid="CR141">141</xref>,<xref ref-type="bibr" rid="CR145">145</xref></sup> Using a lipid centric view, punctate irregular &#x0201c;early&#x0201d; pathology might represent the initial vesicle clustering<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> or lipid droplet formation<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> before the characteristic pathology develops. Overexpression of &#x003b1;syn in yeast models produces lipid only inclusions, lacking the filamentous &#x003b1;syn that is the hallmark of synucleinopathies.<sup><xref ref-type="bibr" rid="CR146">146</xref></sup> Lipids have been identified as a core component of Lewy pathology<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR147">147</xref>,<xref ref-type="bibr" rid="CR148">148</xref></sup> but this has largely been ignored and the pathology is often considered &#x0201c;proteinaceous.&#x0201d;</p><p id="Par17">Recent work by Shahmoradian and colleagues<sup><xref ref-type="bibr" rid="CR149">149</xref></sup> provided substantial evidence that Lewy pathology consists of compacted lipid components from a variety of organelles with &#x003b1;syn oligomers interspersed. Their work strongly suggests that Lewy pathology is actually an inclusion of fragmented lipids, for which &#x003b1;syn&#x02013;lipid interactions play a causative role. Ultrastructural characterization of Lewy pathology showed tubule vesicular, fragmented membranous, and mixed lipid&#x02013;protein structures, all of which can be formed from &#x003b1;syn interactions with vesicle membranes. Electron dense structures, consistent with lysosomes, were also observed throughout Lewy pathology.<sup><xref ref-type="bibr" rid="CR149">149</xref></sup> Lysosomes are central mediators of lipid metabolism<sup><xref ref-type="bibr" rid="CR150">150</xref></sup> and the conspicuous presence of lysosomes surrounded by fragmented membrane structures strongly suggests a deficit in lysosomal/autophagic pathways, specifically the removal of lipid membranes. Large-scale genome-wide association studies have implicated lysosomal/autophagy pathway in several neurodegerative diseases, including synucleinopathies.<sup><xref ref-type="bibr" rid="CR151">151</xref>,<xref ref-type="bibr" rid="CR152">152</xref></sup></p><p id="Par18">A lipid-centric view of Lewy pathology is transformative in that it helps unify and identify disease-causing pathology of several molecular origins. Several neurodegenerative diseases are currently characterized by protein aggregation, when instead we may be missing the lipid components that are the core of the pathology. For example, clinical cases resembling synucleinopathies are documented without the presence of Lewy pathology (e.g., Parkin mutations with early-onset Parkinson&#x02019;s disease), as measured by &#x003b1;syn staining.<sup><xref ref-type="bibr" rid="CR153">153</xref></sup> The presence of lipid inclusions in the absence of &#x003b1;syn are not generally considered when examining patient tissues.</p></sec><sec id="Sec7"><title>Determining &#x003b1;syn&#x02013;lipids interactions in living cells</title><p id="Par19">&#x003b1;Syn interactions with lipids and vesicles has been investigated mostly in vitro and needs to be characterized in living cells. There are several promising strategies to start understanding lipid&#x02013;&#x003b1;syn interactions. The first strategy uses synthetic bifunctional lipids to directly determine lipid&#x02013;protein interactions.<sup><xref ref-type="bibr" rid="CR154">154</xref>,<xref ref-type="bibr" rid="CR155">155</xref></sup> This strategy offers flexibility with analysis and offers unambiguous evidence of direct &#x003b1;syn&#x02013;lipid interactions in vivo. Captured lipid&#x02013;&#x003b1;syn molecules can be subsequently labeled or purified for downstream analysis. Labeling the structures will help determine where &#x003b1;syn&#x02013;lipid interactions are most relevant in the cell. Purification of the structures with subsequent analysis by liquid chromatography&#x02013;mass spectrometry could determine specific &#x003b1;syn proteoforms involved with pathological lipid interactions, as well as global analysis of other proteins that are involved. However, the drawback to this strategy is the investigator can only assess one specific lipid species at a time and a synthetic bifunctional lipid must be available or developed for application. Recently, a bifunctional analog of glucosylceramide, a lipid implicated in synucleinopathy,<sup><xref ref-type="bibr" rid="CR156">156</xref></sup> has become commercially available and could aid in these studies.</p><p id="Par20">A shotgun lipidomic analysis may also be useful, but because of the complexity of whole-cell lipid determination, the data may not give insight into the localized &#x003b1;syn&#x02013;lipid interactions that precede pathology formation. Recently, a shotgun lipodomic analysis was conducted on various &#x003b1;syn mutant models and &#x003b1;syn was found to have an effect on lipid metabolism.<sup><xref ref-type="bibr" rid="CR49">49</xref></sup> However, it is difficult to draw distinct conclusions or find drug targets based on the description of a total lipid species. The resulting information is most useful in implicating lipid metabolism or catabolism pathways, and not the characterization of the specific localized lipids that may be involved with initiating pathology. To find a disease-relevant target, a focused lipodomic approach looking at specific organelles, or better yet, early Lewy pathology, will be the most illuminating. Lipodomic arrays can also be used to screen many lipid&#x02013;protein interactions; however, they have the disadvantage of not representing in vivo binding conditions.</p><p id="Par21">A key question remains: at what point during its interaction with cytoplasmic membranes and extracellular vesicles does &#x003b1;syn adopt a pathological confirmation? To answer this question, one needs to consider the membrane as a chemical reactor favoring molecular encounters.<sup><xref ref-type="bibr" rid="CR134">134</xref></sup> This is the consequence that restrains monomeric or low-molecular-weight oligomeric &#x003b1;syn diffusion from a three-dimensional to a 2D space upon interaction with the plasma membrane or extracellular vesicles plane.</p></sec><sec id="Sec8" sec-type="conclusion"><title>Conclusions</title><p id="Par22">Evidence for a soluble &#x003b1;syn oligomer might be best explained by folding intermediates on the plasma or vesicle membranes that remain soluble for subsequent extraction and detection. This interpretation does not require a soluble functional oligomer and seems to fit much of the experimental data. The distinction between a soluble native oligomer and vesicle-bound oligomers/folding intermediates is important, because it clarifies the origins of pathological aggregation of &#x003b1;syn. With this perspective, determining the molecular details of &#x003b1;syn&#x02013;vesicle/lipid interactions is important for understanding the endogenous origins of synucleinopathy. Although there is consensus that aggregation of &#x003b1;syn is associated with neurological disease, the precise molecular origin of the aggregate pathology remains a mystery.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>B.A.K. and J.H.K. conceived and prepared the manuscript. R.M. and P.B. provided valuable discussion, as well as reviewed and edited the manuscript.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par23">P.B. has received commercial support as a consultant from Axial Biotherapeutics, CuraSen, Fujifilm-Cellular Dynamics International, IOS Press Partners, LifeSci Capital, and Living Cell Technologies Ltd. He has received commercial support for grants/research from Lundbeck A/S and Roche. He has ownership interests in Acousort AB and Axial Biotherapeutics and is on the steering committee of the NILO-PD trial. J.H.K. has received commercial support as a consultant from Cellular Dynamics International, Inc., Michael J. Fox Foundation, Abbvie, Exicure, NSGENE, Guidepoint, Inhibikhase, Axovant, and Seelos B.A.K. and R.M. have no competing interests to disclose.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCann</surname><given-names>H</given-names></name><name><surname>Stevens</surname><given-names>CH</given-names></name><name><surname>Cartwright</surname><given-names>H</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name></person-group><article-title>Alpha-synucleinopathy phenotypes</article-title><source>Parkinsonism Relat. Disord.</source><year>2014</year><volume>20</volume><fpage>S62</fpage><lpage>S67</lpage><pub-id pub-id-type="doi">10.1016/S1353-8020(13)70017-8</pub-id><?supplied-pmid 24262191?><pub-id pub-id-type="pmid">24262191</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fusco</surname><given-names>G</given-names></name><etal/></person-group><article-title>Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers</article-title><source>Science</source><year>2017</year><volume>358</volume><fpage>1440</fpage><lpage>1443</lpage><pub-id pub-id-type="doi">10.1126/science.aan6160</pub-id><?supplied-pmid 29242346?><pub-id pub-id-type="pmid">29242346</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froula</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Defining alpha-synuclein species responsible for Parkinson disease phenotypes in mice</article-title><source>J. Biol. Chem.</source><year>2019</year><pub-id pub-id-type="doi">10.1074/jbc.RA119.007743</pub-id><?supplied-pmid 31142553?><pub-id pub-id-type="pmid">31142553</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakur</surname><given-names>P</given-names></name><etal/></person-group><article-title>Modeling Parkinson&#x02019;s disease pathology by combination of fibril seeds and alpha-synuclein overexpression in the rat brain</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>E8284</fpage><lpage>E8293</lpage><pub-id pub-id-type="doi">10.1073/pnas.1710442114</pub-id><?supplied-pmid 28900002?><pub-id pub-id-type="pmid">28900002</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>20051</fpage><lpage>20056</lpage><pub-id pub-id-type="doi">10.1073/pnas.0908005106</pub-id><?supplied-pmid 19892735?><pub-id pub-id-type="pmid">19892735</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volpicelli-Daley</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death</article-title><source>Neuron</source><year>2011</year><volume>72</volume><fpage>57</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.08.033</pub-id><?supplied-pmid 21982369?><pub-id pub-id-type="pmid">21982369</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice</article-title><source>J. Exp. Med.</source><year>2012</year><volume>209</volume><fpage>975</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1084/jem.20112457</pub-id><?supplied-pmid 22508839?><pub-id pub-id-type="pmid">22508839</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartels</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>JG</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation</article-title><source>Nature</source><year>2011</year><volume>477</volume><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nature10324</pub-id><?supplied-pmid 21841800?><pub-id pub-id-type="pmid">21841800</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burre</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Sudhof</surname><given-names>TC</given-names></name></person-group><article-title>Alpha-synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>E4274</fpage><lpage>4283</lpage><pub-id pub-id-type="doi">10.1073/pnas.1416598111</pub-id><?supplied-pmid 25246573?><pub-id pub-id-type="pmid">25246573</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burre</surname><given-names>J</given-names></name><etal/></person-group><article-title>Properties of native brain alpha-synuclein</article-title><source>Nature</source><year>2013</year><volume>498</volume><fpage>E4</fpage><lpage>E6</lpage><pub-id pub-id-type="doi">10.1038/nature12125</pub-id><?supplied-pmid 23765500?><pub-id pub-id-type="pmid">23765500</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winner</surname><given-names>B</given-names></name><etal/></person-group><article-title>In vivo demonstration that alpha-synuclein oligomers are toxic</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>4194</fpage><lpage>4199</lpage><pub-id pub-id-type="doi">10.1073/pnas.1100976108</pub-id><?supplied-pmid 21325059?><pub-id pub-id-type="pmid">21325059</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremades</surname><given-names>N</given-names></name><etal/></person-group><article-title>Direct observation of the interconversion of normal and toxic forms of alpha-synuclein</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>1048</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.037</pub-id><?supplied-pmid 22632969?><pub-id pub-id-type="pmid">22632969</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forloni</surname><given-names>G</given-names></name><name><surname>Artuso</surname><given-names>V</given-names></name><name><surname>La Vitola</surname><given-names>P</given-names></name><name><surname>Balducci</surname><given-names>C</given-names></name></person-group><article-title>Oligomeropathies and pathogenesis of Alzheimer and Parkinson&#x02019;s diseases</article-title><source>Mov. Disord.</source><year>2016</year><volume>31</volume><fpage>771</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1002/mds.26624</pub-id><?supplied-pmid 27030592?><pub-id pub-id-type="pmid">27030592</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theillet</surname><given-names>FX</given-names></name><etal/></person-group><article-title>Structural disorder of monomeric alpha-synuclein persists in mammalian cells</article-title><source>Nature</source><year>2016</year><volume>530</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/nature16531</pub-id><?supplied-pmid 26808899?><pub-id pub-id-type="pmid">26808899</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>alpha-synuclein multimers cluster synaptic vesicles and attenuate recycling</article-title><source>Curr. Biol.</source><year>2014</year><volume>24</volume><fpage>2319</fpage><lpage>2326</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.08.027</pub-id><?supplied-pmid 25264250?><pub-id pub-id-type="pmid">25264250</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvagnion</surname><given-names>C</given-names></name></person-group><article-title>The role of lipids interacting with alpha-synuclein in the pathogenesis of Parkinson&#x02019;s disease</article-title><source>J. Parkinsons Dis.</source><year>2017</year><volume>7</volume><fpage>433</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.3233/JPD-171103</pub-id><?supplied-pmid 28671142?><pub-id pub-id-type="pmid">28671142</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Sango</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>K</given-names></name><name><surname>Nagai</surname><given-names>Y</given-names></name></person-group><article-title>Pathological role of lipid interaction with alpha-synuclein in Parkinson&#x02019;s disease</article-title><source>Neurochem. Int.</source><year>2018</year><volume>119</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2017.12.014</pub-id><?supplied-pmid 29305919?><pub-id pub-id-type="pmid">29305919</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snead</surname><given-names>D</given-names></name><name><surname>Eliezer</surname><given-names>D</given-names></name></person-group><article-title>Alpha-synuclein function and dysfunction on cellular membranes</article-title><source>Exp. Neurobiol.</source><year>2014</year><volume>23</volume><fpage>292</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.5607/en.2014.23.4.292</pub-id><?supplied-pmid 25548530?><pub-id pub-id-type="pmid">25548530</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alza</surname><given-names>NP</given-names></name><name><surname>Iglesias Gonzalez</surname><given-names>PA</given-names></name><name><surname>Conde</surname><given-names>MA</given-names></name><name><surname>Uranga</surname><given-names>RM</given-names></name><name><surname>Salvador</surname><given-names>GA</given-names></name></person-group><article-title>Lipids at the crossroad of alpha-synuclein function and dysfunction: biological and pathological implications</article-title><source>Front. Cell. Neurosci.</source><year>2019</year><volume>13</volume><fpage>175</fpage><pub-id pub-id-type="doi">10.3389/fncel.2019.00175</pub-id><?supplied-pmid 31118888?><pub-id pub-id-type="pmid">31118888</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Leary</surname><given-names>EI</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name></person-group><article-title>Interplay between alpha-synuclein amyloid formation and membrane structure. <italic>Biochimica et biophysica acta</italic></article-title><source>Biochim. Biphys. Acta Proteins Proteom.</source><year>2019</year><volume>1867</volume><fpage>483</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2018.09.012</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alecu</surname><given-names>I</given-names></name><name><surname>Bennett</surname><given-names>SAL</given-names></name></person-group><article-title>Dysregulated lipid metabolism and its role in alpha-synucleinopathy in Parkinson&#x02019;s disease</article-title><source>Front. Neurosci.</source><year>2019</year><volume>13</volume><fpage>328</fpage><pub-id pub-id-type="doi">10.3389/fnins.2019.00328</pub-id><?supplied-pmid 31031582?><pub-id pub-id-type="pmid">31031582</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengoa-Vergniory</surname><given-names>N</given-names></name><name><surname>Roberts</surname><given-names>RF</given-names></name><name><surname>Wade-Martins</surname><given-names>R</given-names></name><name><surname>Alegre-Abarrategui</surname><given-names>J</given-names></name></person-group><article-title>Alpha-synuclein oligomers: a new hope</article-title><source>Acta Neuropathol.</source><year>2017</year><volume>134</volume><fpage>819</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1007/s00401-017-1755-1</pub-id><?supplied-pmid 28803412?><pub-id pub-id-type="pmid">28803412</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lashuel</surname><given-names>HA</given-names></name><name><surname>Overk</surname><given-names>CR</given-names></name><name><surname>Oueslati</surname><given-names>A</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name></person-group><article-title>The many faces of alpha-synuclein: from structure and toxicity to therapeutic target</article-title><source>Nat. Rev. Neurosci.</source><year>2013</year><volume>14</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/nrn3406</pub-id><?supplied-pmid 23254192?><pub-id pub-id-type="pmid">23254192</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Brien</surname><given-names>JS</given-names></name><name><surname>Sampson</surname><given-names>EL</given-names></name></person-group><article-title>Lipid composition of the normal human brain: gray matter, white matter, and myelin</article-title><source>J. Lipid Res.</source><year>1965</year><volume>6</volume><fpage>537</fpage><lpage>544</lpage><?supplied-pmid 5865382?><pub-id pub-id-type="pmid">5865382</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muro</surname><given-names>E</given-names></name><name><surname>Atilla-Gokcumen</surname><given-names>GE</given-names></name><name><surname>Eggert</surname><given-names>US</given-names></name></person-group><article-title>Lipids in cell biology: how can we understand them better?</article-title><source>Mol. Biol. Cell</source><year>2014</year><volume>25</volume><fpage>1819</fpage><lpage>1823</lpage><pub-id pub-id-type="doi">10.1091/mbc.e13-09-0516</pub-id><?supplied-pmid 24925915?><pub-id pub-id-type="pmid">24925915</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adibhatla</surname><given-names>RM</given-names></name><name><surname>Hatcher</surname><given-names>JF</given-names></name></person-group><article-title>Role of lipids in brain injury and diseases</article-title><source>Future Lipidol.</source><year>2007</year><volume>2</volume><fpage>403</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.2217/17460875.2.4.403</pub-id><?supplied-pmid 18176634?><pub-id pub-id-type="pmid">18176634</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugger</surname><given-names>B</given-names></name></person-group><article-title>Lipidomics: analysis of the lipid composition of cells and subcellular organelles by electrospray ionization mass spectrometry</article-title><source>Annu. Rev. Biochem.</source><year>2014</year><volume>83</volume><fpage>79</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060713-035324</pub-id><?supplied-pmid 24606142?><pub-id pub-id-type="pmid">24606142</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lydic</surname><given-names>TA</given-names></name><name><surname>Goo</surname><given-names>YH</given-names></name></person-group><article-title>Lipidomics unveils the complexity of the lipidome in metabolic diseases</article-title><source>Clin. Transl. Med.</source><year>2018</year><volume>7</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s40169-018-0182-9</pub-id><?supplied-pmid 29374337?><pub-id pub-id-type="pmid">29374337</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>X</given-names></name></person-group><article-title>Lipidomics: techniques, applications, and outcomes related to biomedical sciences</article-title><source>Trends Biochem. Sci.</source><year>2016</year><volume>41</volume><fpage>954</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2016.08.010</pub-id><?supplied-pmid 27663237?><pub-id pub-id-type="pmid">27663237</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saliba</surname><given-names>AE</given-names></name><name><surname>Vonkova</surname><given-names>I</given-names></name><name><surname>Gavin</surname><given-names>AC</given-names></name></person-group><article-title>The systematic analysis of protein-lipid interactions comes of age</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2015</year><volume>16</volume><fpage>753</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1038/nrm4080</pub-id><?supplied-pmid 26507169?><pub-id pub-id-type="pmid">26507169</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Alpha-synuclein in Lewy bodies</article-title><source>Nature</source><year>1997</year><volume>388</volume><fpage>839</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1038/42166</pub-id><?supplied-pmid 9278044?><pub-id pub-id-type="pmid">9278044</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>PH</given-names></name><name><surname>Nielsen</surname><given-names>MS</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Dotti</surname><given-names>CG</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><article-title>Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson&#x02019;s disease mutation</article-title><source>J. Biol. Chem.</source><year>1998</year><volume>273</volume><fpage>26292</fpage><lpage>26294</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.41.26292</pub-id><?supplied-pmid 9756856?><pub-id pub-id-type="pmid">9756856</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>den Jager</surname><given-names>WA</given-names></name></person-group><article-title>Sphingomyelin in Lewy inclusion bodies in Parkinson&#x02019;s disease</article-title><source>Arch. Neurol.</source><year>1969</year><volume>21</volume><fpage>615</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1001/archneur.1969.00480180071006</pub-id><pub-id pub-id-type="pmid">4187718</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burre</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Sudhof</surname><given-names>TC</given-names></name></person-group><article-title>Definition of a molecular pathway mediating alpha-synuclein neurotoxicity</article-title><source>J. Neurosci.</source><year>2015</year><volume>35</volume><fpage>5221</fpage><lpage>5232</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4650-14.2015</pub-id><?supplied-pmid 25834048?><pub-id pub-id-type="pmid">25834048</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>ML</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>WJ</given-names></name></person-group><article-title>Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies</article-title><source>J. Neurosci.</source><year>2007</year><volume>27</volume><fpage>1405</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4564-06.2007</pub-id><?supplied-pmid 17287515?><pub-id pub-id-type="pmid">17287515</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson&#x02019;s disease</article-title><source>Brain</source><year>2005</year><volume>128</volume><fpage>2654</fpage><lpage>2664</lpage><pub-id pub-id-type="doi">10.1093/brain/awh584</pub-id><?supplied-pmid 16000336?><pub-id pub-id-type="pmid">16000336</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvagnion</surname><given-names>C</given-names></name><etal/></person-group><article-title>Lipid vesicles trigger alpha-synuclein aggregation by stimulating primary nucleation</article-title><source>Nat. Chem. Biol.</source><year>2015</year><volume>11</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1750</pub-id><?supplied-pmid 25643172?><pub-id pub-id-type="pmid">25643172</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fink</surname><given-names>AL</given-names></name></person-group><article-title>The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>40186</fpage><lpage>40197</lpage><pub-id pub-id-type="doi">10.1074/jbc.M305326200</pub-id><?supplied-pmid 12885775?><pub-id pub-id-type="pmid">12885775</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Choi</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name></person-group><article-title>Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>671</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1074/jbc.M107045200</pub-id><?supplied-pmid 11679584?><pub-id pub-id-type="pmid">11679584</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grey</surname><given-names>M</given-names></name><etal/></person-group><article-title>Acceleration of alpha-synuclein aggregation by exosomes</article-title><source>J. Biol. Chem.</source><year>2015</year><volume>290</volume><fpage>2969</fpage><lpage>2982</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.585703</pub-id><?supplied-pmid 25425650?><pub-id pub-id-type="pmid">25425650</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>E</given-names></name><name><surname>Fuller</surname><given-names>N</given-names></name><name><surname>Rand</surname><given-names>RPSt</given-names></name><name><surname>George-Hyslop</surname><given-names>P</given-names></name><name><surname>Fraser</surname><given-names>PE</given-names></name></person-group><article-title>Defective membrane interactions of familial Parkinson&#x02019;s disease mutant A30P alpha-synuclein</article-title><source>J. Mol. Biol.</source><year>2002</year><volume>315</volume><fpage>799</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1006/jmbi.2001.5269</pub-id><?supplied-pmid 11812148?><pub-id pub-id-type="pmid">11812148</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fares</surname><given-names>MB</given-names></name><etal/></person-group><article-title>The novel Parkinson&#x02019;s disease linked mutation G51D attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells</article-title><source>Hum. Mol. Genet.</source><year>2014</year><volume>23</volume><fpage>4491</fpage><lpage>4509</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu165</pub-id><?supplied-pmid 24728187?><pub-id pub-id-type="pmid">24728187</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>D</given-names></name><etal/></person-group><article-title>The newly discovered Parkinson&#x02019;s disease associated Finnish mutation (A53E) attenuates alpha-synuclein aggregation and membrane binding</article-title><source>Biochem</source><year>2014</year><volume>53</volume><fpage>6419</fpage><lpage>6421</lpage><pub-id pub-id-type="doi">10.1021/bi5010365</pub-id><pub-id pub-id-type="pmid">25268550</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robotta</surname><given-names>M</given-names></name><name><surname>Cattani</surname><given-names>J</given-names></name><name><surname>Martins</surname><given-names>JC</given-names></name><name><surname>Subramaniam</surname><given-names>V</given-names></name><name><surname>Drescher</surname><given-names>M</given-names></name></person-group><article-title>Alpha-synuclein disease mutations are structurally defective and locally affect membrane binding</article-title><source>J. Am. Chem. Soc.</source><year>2017</year><volume>139</volume><fpage>4254</fpage><lpage>4257</lpage><pub-id pub-id-type="doi">10.1021/jacs.6b05335</pub-id><?supplied-pmid 28298083?><pub-id pub-id-type="pmid">28298083</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kara</surname><given-names>E</given-names></name><etal/></person-group><article-title>alpha-Synuclein mutations cluster around a putative protein loop</article-title><source>Neurosci. Lett.</source><year>2013</year><volume>546</volume><fpage>67</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2013.04.058</pub-id><?supplied-pmid 23669636?><pub-id pub-id-type="pmid">23669636</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flagmeier</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mutations associated with familial Parkinson&#x02019;s disease alter the initiation and amplification steps of alpha-synuclein aggregation</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>10328</fpage><lpage>10333</lpage><pub-id pub-id-type="doi">10.1073/pnas.1604645113</pub-id><?supplied-pmid 27573854?><pub-id pub-id-type="pmid">27573854</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>NB</given-names></name><etal/></person-group><article-title>Lipid droplet binding and oligomerization properties of the Parkinson&#x02019;s disease protein alpha-synuclein</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>6344</fpage><lpage>6352</lpage><pub-id pub-id-type="doi">10.1074/jbc.M108414200</pub-id><?supplied-pmid 11744721?><pub-id pub-id-type="pmid">11744721</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuber</surname><given-names>S</given-names></name><etal/></person-group><article-title>Abrogating native alpha-synuclein tetramers in mice causes a L-DOPA-responsive motor syndrome closely resembling Parkinson&#x02019;s disease</article-title><source>Neuron</source><year>2018</year><volume>100</volume><fpage>75</fpage><lpage>90 e75</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.09.014</pub-id><?supplied-pmid 30308173?><pub-id pub-id-type="pmid">30308173</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanning</surname><given-names>S</given-names></name><etal/></person-group><article-title>Lipidomic analysis of alpha-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment</article-title><source>Mol. Cell</source><year>2019</year><volume>73</volume><fpage>1001</fpage><lpage>1014 e1008</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.11.028</pub-id><?supplied-pmid 30527540?><pub-id pub-id-type="pmid">30527540</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burre</surname><given-names>J</given-names></name></person-group><article-title>The synaptic function of alpha-synuclein</article-title><source>J. Parkinsons Dis.</source><year>2015</year><volume>5</volume><fpage>699</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.3233/JPD-150642</pub-id><?supplied-pmid 26407041?><pub-id pub-id-type="pmid">26407041</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name></person-group><article-title>alpha-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis</article-title><source>J. Neurosci.</source><year>2012</year><volume>32</volume><fpage>10129</fpage><lpage>10135</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0535-12.2012</pub-id><?supplied-pmid 22836248?><pub-id pub-id-type="pmid">22836248</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis</article-title><source>J. Neurosci.</source><year>2006</year><volume>26</volume><fpage>11915</fpage><lpage>11922</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3821-06.2006</pub-id><?supplied-pmid 17108165?><pub-id pub-id-type="pmid">17108165</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemani</surname><given-names>VM</given-names></name><etal/></person-group><article-title>Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis</article-title><source>Neuron</source><year>2010</year><volume>65</volume><fpage>66</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2009.12.023</pub-id><?supplied-pmid 20152114?><pub-id pub-id-type="pmid">20152114</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busch</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Acute increase of alpha-synuclein inhibits synaptic vesicle recycling evoked during intense stimulation</article-title><source>Mol. Biol. Cell</source><year>2014</year><volume>25</volume><fpage>3926</fpage><lpage>3941</lpage><pub-id pub-id-type="doi">10.1091/mbc.e14-02-0708</pub-id><?supplied-pmid 25273557?><pub-id pub-id-type="pmid">25273557</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lautenschlager</surname><given-names>J</given-names></name><name><surname>Kaminski</surname><given-names>CF</given-names></name><name><surname>Kaminski Schierle</surname><given-names>G</given-names></name></person-group><article-title>S. alpha-synuclein - regulator of exocytosis, endocytosis, or both?</article-title><source>Trends Cell Biol.</source><year>2017</year><volume>27</volume><fpage>468</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2017.02.002</pub-id><?supplied-pmid 28259601?><pub-id pub-id-type="pmid">28259601</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>DD</given-names></name><name><surname>Rueter</surname><given-names>SM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name></person-group><article-title>Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons</article-title><source>J. Neurosci.</source><year>2000</year><volume>20</volume><fpage>3214</fpage><lpage>3220</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-09-03214.2000</pub-id><?supplied-pmid 10777786?><pub-id pub-id-type="pmid">10777786</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabin</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein</article-title><source>J. Neurosci.</source><year>2002</year><volume>22</volume><fpage>8797</fpage><lpage>8807</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-20-08797.2002</pub-id><?supplied-pmid 12388586?><pub-id pub-id-type="pmid">12388586</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fusco</surname><given-names>G</given-names></name><etal/></person-group><article-title>Structural basis of synaptic vesicle assembly promoted by alpha-synuclein</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>12563</fpage><pub-id pub-id-type="doi">10.1038/ncomms12563</pub-id><?supplied-pmid 27640673?><pub-id pub-id-type="pmid">27640673</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgieva</surname><given-names>ER</given-names></name><name><surname>Ramlall</surname><given-names>TF</given-names></name><name><surname>Borbat</surname><given-names>PP</given-names></name><name><surname>Freed</surname><given-names>JH</given-names></name><name><surname>Eliezer</surname><given-names>D</given-names></name></person-group><article-title>Membrane-bound alpha-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles</article-title><source>J. Am. Chem. Soc.</source><year>2008</year><volume>130</volume><fpage>12856</fpage><lpage>12857</lpage><pub-id pub-id-type="doi">10.1021/ja804517m</pub-id><?supplied-pmid 18774805?><pub-id pub-id-type="pmid">18774805</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Nass, R. a. P., S. <italic>Parkinson&#x02019;s Disease: Molecular and Therapeutic Insights from Model Systems</italic> (Elsevier, 2008).</mixed-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgieva</surname><given-names>ER</given-names></name><name><surname>Ramlall</surname><given-names>TF</given-names></name><name><surname>Borbat</surname><given-names>PP</given-names></name><name><surname>Freed</surname><given-names>JH</given-names></name><name><surname>Eliezer</surname><given-names>D</given-names></name></person-group><article-title>The lipid-binding domain of wild type and mutant alpha-synuclein: compactness and interconversion between the broken and extended helix forms</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>28261</fpage><lpage>28274</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.157214</pub-id><?supplied-pmid 20592036?><pub-id pub-id-type="pmid">20592036</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharon</surname><given-names>R</given-names></name><etal/></person-group><article-title>alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>9110</fpage><lpage>9115</lpage><pub-id pub-id-type="doi">10.1073/pnas.171300598</pub-id><?supplied-pmid 11481478?><pub-id pub-id-type="pmid">11481478</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesmin</surname><given-names>B</given-names></name><etal/></person-group><article-title>A four-step cycle driven by PI(4)P hydrolysis directs sterol/PI(4)P exchange by the ER-Golgi tether OSBP</article-title><source>Cell</source><year>2013</year><volume>155</volume><fpage>830</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.09.056</pub-id><?supplied-pmid 24209621?><pub-id pub-id-type="pmid">24209621</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lev</surname><given-names>S</given-names></name></person-group><article-title>Non-vesicular lipid transport by lipid-transfer proteins and beyond</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2010</year><volume>11</volume><fpage>739</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1038/nrm2971</pub-id><?supplied-pmid 20823909?><pub-id pub-id-type="pmid">20823909</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouberai</surname><given-names>MM</given-names></name><etal/></person-group><article-title>alpha-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>20883</fpage><lpage>20895</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.478297</pub-id><?supplied-pmid 23740253?><pub-id pub-id-type="pmid">23740253</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garten</surname><given-names>M</given-names></name><etal/></person-group><article-title>Methyl-branched lipids promote the membrane adsorption of alpha-synuclein by enhancing shallow lipid-packing defects</article-title><source>Phys. Chem. Chem. Phys.</source><year>2015</year><volume>17</volume><fpage>15589</fpage><lpage>15597</lpage><pub-id pub-id-type="doi">10.1039/C5CP00244C</pub-id><?supplied-pmid 25824255?><pub-id pub-id-type="pmid">25824255</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuscher</surname><given-names>B</given-names></name><etal/></person-group><article-title>Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>21966</fpage><lpage>21975</lpage><pub-id pub-id-type="doi">10.1074/jbc.M401076200</pub-id><?supplied-pmid 15028717?><pub-id pub-id-type="pmid">15028717</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamp</surname><given-names>F</given-names></name><name><surname>Beyer</surname><given-names>K</given-names></name></person-group><article-title>Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>9251</fpage><lpage>9259</lpage><pub-id pub-id-type="doi">10.1074/jbc.M512292200</pub-id><?supplied-pmid 16455667?><pub-id pub-id-type="pmid">16455667</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Middleton</surname><given-names>ER</given-names></name><name><surname>Rhoades</surname><given-names>E</given-names></name></person-group><article-title>Effects of curvature and composition on alpha-synuclein binding to lipid vesicles</article-title><source>Biophys. J.</source><year>2010</year><volume>99</volume><fpage>2279</fpage><lpage>2288</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2010.07.056</pub-id><?supplied-pmid 20923663?><pub-id pub-id-type="pmid">20923663</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pranke</surname><given-names>IM</given-names></name><etal/></person-group><article-title>alpha-Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding</article-title><source>J. Cell Biol.</source><year>2011</year><volume>194</volume><fpage>89</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1083/jcb.201011118</pub-id><?supplied-pmid 21746853?><pub-id pub-id-type="pmid">21746853</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjaer</surname><given-names>L</given-names></name><name><surname>Giehm</surname><given-names>L</given-names></name><name><surname>Heimburg</surname><given-names>T</given-names></name><name><surname>Otzen</surname><given-names>D</given-names></name></person-group><article-title>The influence of vesicle size and composition on alpha-synuclein structure and stability</article-title><source>Biophys. J.</source><year>2009</year><volume>96</volume><fpage>2857</fpage><lpage>2870</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2008.12.3940</pub-id><?supplied-pmid 19348768?><pub-id pub-id-type="pmid">19348768</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Leary</surname><given-names>EI</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Strub</surname><given-names>MP</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name></person-group><article-title>Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated alpha-synuclein</article-title><source>J. Biol. Chem.</source><year>2018</year><volume>293</volume><fpage>11195</fpage><lpage>11205</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.002780</pub-id><?supplied-pmid 29853639?><pub-id pub-id-type="pmid">29853639</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boassa</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mapping the subcellular distribution of alpha-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson&#x02019;s disease pathogenesis</article-title><source>J. Neurosci.</source><year>2013</year><volume>33</volume><fpage>2605</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2898-12.2013</pub-id><?supplied-pmid 23392688?><pub-id pub-id-type="pmid">23392688</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Rizo</surname><given-names>J</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name><name><surname>Sudhof</surname><given-names>TC</given-names></name></person-group><article-title>A broken alpha -helix in folded alpha-synuclein</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>15313</fpage><lpage>15318</lpage><pub-id pub-id-type="doi">10.1074/jbc.M213128200</pub-id><?supplied-pmid 12586824?><pub-id pub-id-type="pmid">12586824</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>WS</given-names></name><name><surname>Jonas</surname><given-names>A</given-names></name><name><surname>Clayton</surname><given-names>DF</given-names></name><name><surname>George</surname><given-names>JM</given-names></name></person-group><article-title>Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes</article-title><source>J. Biol. Chem.</source><year>1998</year><volume>273</volume><fpage>9443</fpage><lpage>9449</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.16.9443</pub-id><?supplied-pmid 9545270?><pub-id pub-id-type="pmid">9545270</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellstrand</surname><given-names>E</given-names></name><etal/></person-group><article-title>Adsorption of alpha-synuclein to supported lipid bilayers: positioning and role of electrostatics</article-title><source>ACS Chem. Neurosci.</source><year>2013</year><volume>4</volume><fpage>1339</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1021/cn400066t</pub-id><?supplied-pmid 23823878?><pub-id pub-id-type="pmid">23823878</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreon</surname><given-names>AC</given-names></name><name><surname>Gambin</surname><given-names>Y</given-names></name><name><surname>Lemke</surname><given-names>EA</given-names></name><name><surname>Deniz</surname><given-names>AA</given-names></name></person-group><article-title>Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>5645</fpage><lpage>5650</lpage><pub-id pub-id-type="doi">10.1073/pnas.0809232106</pub-id><?supplied-pmid 19293380?><pub-id pub-id-type="pmid">19293380</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trexler</surname><given-names>AJ</given-names></name><name><surname>Rhoades</surname><given-names>E</given-names></name></person-group><article-title>Alpha-synuclein binds large unilamellar vesicles as an extended helix</article-title><source>Biochem</source><year>2009</year><volume>48</volume><fpage>2304</fpage><lpage>2306</lpage><pub-id pub-id-type="doi">10.1021/bi900114z</pub-id><pub-id pub-id-type="pmid">19220042</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jao</surname><given-names>CC</given-names></name><name><surname>Hegde</surname><given-names>BG</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Haworth</surname><given-names>IS</given-names></name><name><surname>Langen</surname><given-names>R</given-names></name></person-group><article-title>Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>19666</fpage><lpage>19671</lpage><pub-id pub-id-type="doi">10.1073/pnas.0807826105</pub-id><?supplied-pmid 19066219?><pub-id pub-id-type="pmid">19066219</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussell</surname><given-names>R</given-names><suffix>Jr.</suffix></name><name><surname>Eliezer</surname><given-names>D</given-names></name></person-group><article-title>A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins</article-title><source>J. Mol. Biol.</source><year>2003</year><volume>329</volume><fpage>763</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(03)00520-5</pub-id><?supplied-pmid 12787676?><pub-id pub-id-type="pmid">12787676</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>E</given-names></name><name><surname>McLaurin</surname><given-names>J</given-names></name><name><surname>Yip</surname><given-names>CMSt</given-names></name><name><surname>George-Hyslop</surname><given-names>P</given-names></name><name><surname>Fraser</surname><given-names>P</given-names></name></person-group><article-title>E. alpha-Synuclein membrane interactions and lipid specificity</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>34328</fpage><lpage>34334</lpage><pub-id pub-id-type="doi">10.1074/jbc.M004345200</pub-id><?supplied-pmid 10915790?><pub-id pub-id-type="pmid">10915790</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fusco</surname><given-names>G</given-names></name><etal/></person-group><article-title>Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3827</fpage><pub-id pub-id-type="doi">10.1038/ncomms4827</pub-id><?supplied-pmid 24871041?><pub-id pub-id-type="pmid">24871041</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giasson</surname><given-names>BI</given-names></name><name><surname>Murray</surname><given-names>IV</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name></person-group><article-title>A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>2380</fpage><lpage>2386</lpage><pub-id pub-id-type="doi">10.1074/jbc.M008919200</pub-id><?supplied-pmid 11060312?><pub-id pub-id-type="pmid">11060312</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>T</given-names></name><name><surname>Bendor</surname><given-names>J</given-names></name><name><surname>Toupin</surname><given-names>C</given-names></name><name><surname>Thorn</surname><given-names>K</given-names></name><name><surname>Edwards</surname><given-names>R</given-names></name></person-group><article-title>H. alpha-Synuclein promotes dilation of the exocytotic fusion pore</article-title><source>Nat. Neurosci.</source><year>2017</year><volume>20</volume><fpage>681</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1038/nn.4529</pub-id><?supplied-pmid 28288128?><pub-id pub-id-type="pmid">28288128</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almandoz-Gil</surname><given-names>L</given-names></name><etal/></person-group><article-title>In situ proximity ligation assay reveals co-localization of alpha-synuclein and SNARE proteins in murine primary neurons</article-title><source>Front. Neurol.</source><year>2018</year><volume>9</volume><fpage>180</fpage><pub-id pub-id-type="doi">10.3389/fneur.2018.00180</pub-id><?supplied-pmid 29623065?><pub-id pub-id-type="pmid">29623065</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Hawk</surname><given-names>BJ</given-names></name><name><surname>Shin</surname><given-names>Y</given-names></name></person-group><article-title>K. alpha-Synuclein may cross-bridge v-SNARE and acidic phospholipids to facilitate SNARE-dependent vesicle docking</article-title><source>Biochem. J.</source><year>2017</year><volume>474</volume><fpage>2039</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1042/BCJ20170200</pub-id><?supplied-pmid 28495859?><pub-id pub-id-type="pmid">28495859</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><etal/></person-group><article-title>Functional cooperation of alpha-synuclein and VAMP2 in synaptic vesicle recycling</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2019</year><pub-id pub-id-type="doi">10.1073/pnas.1903049116</pub-id><?supplied-pmid 31662475?><pub-id pub-id-type="pmid">31662475</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atias</surname><given-names>M</given-names></name><etal/></person-group><article-title>Synapsins regulate alpha-synuclein functions</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2019</year><pub-id pub-id-type="doi">10.1073/pnas.1903054116</pub-id><?supplied-pmid 31110014?><pub-id pub-id-type="pmid">31110014</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burre</surname><given-names>J</given-names></name><etal/></person-group><article-title>Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro</article-title><source>Science</source><year>2010</year><volume>329</volume><fpage>1663</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1126/science.1195227</pub-id><?supplied-pmid 20798282?><pub-id pub-id-type="pmid">20798282</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaspar</surname><given-names>R</given-names></name><name><surname>Pallbo</surname><given-names>J</given-names></name><name><surname>Weininger</surname><given-names>U</given-names></name><name><surname>Linse</surname><given-names>S</given-names></name><name><surname>Sparr</surname><given-names>E</given-names></name></person-group><article-title>Reprint of &#x0201c;Ganglioside lipids accelerate alpha-synuclein amyloid formation&#x0201d;</article-title><source>Biochim. Biophys. Acta Proteins Proteom.</source><year>2019</year><volume>1867</volume><fpage>508</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2019.02.003</pub-id><?supplied-pmid 30878495?><pub-id pub-id-type="pmid">30878495</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodner</surname><given-names>CR</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>Bax</surname><given-names>A</given-names></name></person-group><article-title>Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy</article-title><source>J. Mol. Biol.</source><year>2009</year><volume>390</volume><fpage>775</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2009.05.066</pub-id><?supplied-pmid 19481095?><pub-id pub-id-type="pmid">19481095</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>S</given-names></name><etal/></person-group><article-title>beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson&#x02019;s disease</article-title><source>Science</source><year>2017</year><volume>357</volume><fpage>891</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1126/science.aaf3934</pub-id><?supplied-pmid 28860381?><pub-id pub-id-type="pmid">28860381</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Dodiya</surname><given-names>H</given-names></name><name><surname>Aebischer</surname><given-names>P</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Kordower</surname><given-names>JH</given-names></name></person-group><article-title>Alterations in lysosomal and proteasomal markers in Parkinson&#x02019;s disease: relationship to alpha-synuclein inclusions</article-title><source>Neurobiol. Dis.</source><year>2009</year><volume>35</volume><fpage>385</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2009.05.023</pub-id><?supplied-pmid 19505575?><pub-id pub-id-type="pmid">19505575</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>D</given-names></name><etal/></person-group><article-title>Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson&#x02019;s disease model</article-title><source>NPJ Parkinsons Dis.</source><year>2018</year><volume>4</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1038/s41531-018-0062-4</pub-id><?supplied-pmid 30155513?><pub-id pub-id-type="pmid">30155513</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>V</given-names></name><name><surname>Scarlata</surname><given-names>S</given-names></name></person-group><article-title>Membrane binding and self-association of alpha-synucleins</article-title><source>Biochem</source><year>2001</year><volume>40</volume><fpage>9927</fpage><lpage>9934</lpage><pub-id pub-id-type="doi">10.1021/bi002952n</pub-id><pub-id pub-id-type="pmid">11502187</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Fink</surname><given-names>AL</given-names></name></person-group><article-title>Lipid binding inhibits alpha-synuclein fibril formation</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>16873</fpage><lpage>16877</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210136200</pub-id><?supplied-pmid 12621030?><pub-id pub-id-type="pmid">12621030</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>E</given-names></name><etal/></person-group><article-title>Alpha-synuclein-synaptosomal membrane interactions: implications for fibrillogenesis</article-title><source>Eur. J. Biochem</source><year>2004</year><volume>271</volume><fpage>3180</fpage><lpage>3189</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.2004.04250.x</pub-id><?supplied-pmid 15265037?><pub-id pub-id-type="pmid">15265037</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson&#x02019;s disease, in erythropoietic lineage</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2007</year><volume>358</volume><fpage>104</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.04.108</pub-id><?supplied-pmid 17475220?><pub-id pub-id-type="pmid">17475220</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renella</surname><given-names>R</given-names></name><name><surname>Schlehe</surname><given-names>JS</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name><name><surname>LaVoie</surname><given-names>MJ</given-names></name></person-group><article-title>Genetic deletion of the GATA1-regulated protein alpha-synuclein reduces oxidative stress and nitric oxide synthase levels in mature erythrocytes</article-title><source>Am. J. Hematol.</source><year>2014</year><volume>89</volume><fpage>974</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1002/ajh.23796</pub-id><?supplied-pmid 25043722?><pub-id pub-id-type="pmid">25043722</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherzer</surname><given-names>CR</given-names></name><etal/></person-group><article-title>GATA transcription factors directly regulate the Parkinson&#x02019;s disease-linked gene alpha-synuclein</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>10907</fpage><lpage>10912</lpage><pub-id pub-id-type="doi">10.1073/pnas.0802437105</pub-id><?supplied-pmid 18669654?><pub-id pub-id-type="pmid">18669654</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abd-Elhadi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Total and proteinase K-resistant alpha-synuclein levels in erythrocytes, determined by their ability to bind phospholipids, associate with Parkinson&#x02019;s disease</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>11120</fpage><pub-id pub-id-type="doi">10.1038/srep11120</pub-id><?supplied-pmid 26068055?><pub-id pub-id-type="pmid">26068055</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araki</surname><given-names>K</given-names></name><etal/></person-group><article-title>The localization of alpha-synuclein in the process of differentiation of human erythroid cells</article-title><source>Int. J. Hematol.</source><year>2018</year><volume>108</volume><fpage>130</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1007/s12185-018-2457-8</pub-id><?supplied-pmid 29691802?><pub-id pub-id-type="pmid">29691802</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautier</surname><given-names>EF</given-names></name><etal/></person-group><article-title>Comprehensive proteomic analysis of human erythropoiesis</article-title><source>Cell Rep.</source><year>2016</year><volume>16</volume><fpage>1470</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.06.085</pub-id><?supplied-pmid 27452463?><pub-id pub-id-type="pmid">27452463</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imberdis</surname><given-names>T</given-names></name><name><surname>Fanning</surname><given-names>S</given-names></name><name><surname>Newman</surname><given-names>A</given-names></name><name><surname>Ramalingam</surname><given-names>N</given-names></name><name><surname>Dettmer</surname><given-names>U</given-names></name></person-group><article-title>Studying alpha-synuclein conformation by intact-cell cross-linking</article-title><source>Methods Mol. Biol.</source><year>2019</year><volume>1948</volume><fpage>77</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9124-2_8</pub-id><?supplied-pmid 30771172?><pub-id pub-id-type="pmid">30771172</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group><article-title>GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>798</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1073/pnas.1700465115</pub-id><?supplied-pmid 29311330?><pub-id pub-id-type="pmid">29311330</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dettmer</surname><given-names>U</given-names></name><name><surname>Newman</surname><given-names>AJ</given-names></name><name><surname>von Saucken</surname><given-names>VE</given-names></name><name><surname>Bartels</surname><given-names>T</given-names></name><name><surname>Selkoe</surname><given-names>D</given-names></name></person-group><article-title>KTKEGV repeat motifs are key mediators of normal alpha-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>9596</fpage><lpage>9601</lpage><pub-id pub-id-type="doi">10.1073/pnas.1505953112</pub-id><?supplied-pmid 26153422?><pub-id pub-id-type="pmid">26153422</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killinger</surname><given-names>BA</given-names></name><name><surname>Moszczynska</surname><given-names>A</given-names></name></person-group><article-title>Characterization of alpha-synuclein multimer stoichiometry in complex biological samples by electrophoresis</article-title><source>Anal. Chem.</source><year>2016</year><volume>88</volume><fpage>4071</fpage><lpage>4084</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.6b00419</pub-id><?supplied-pmid 26937787?><pub-id pub-id-type="pmid">26937787</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieri</surname><given-names>L</given-names></name><name><surname>Madiona</surname><given-names>K</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name></person-group><article-title>Structural and functional properties of prefibrillar alpha-synuclein oligomers</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>24526</fpage><pub-id pub-id-type="doi">10.1038/srep24526</pub-id><?supplied-pmid 27075649?><pub-id pub-id-type="pmid">27075649</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luth</surname><given-names>ES</given-names></name><name><surname>Bartels</surname><given-names>T</given-names></name><name><surname>Dettmer</surname><given-names>U</given-names></name><name><surname>Kim</surname><given-names>NC</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Purification of alpha-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity</article-title><source>Biochem</source><year>2015</year><volume>54</volume><fpage>279</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1021/bi501188a</pub-id><pub-id pub-id-type="pmid">25490121</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dettmer</surname><given-names>U</given-names></name><etal/></person-group><article-title>Loss of native alpha-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells</article-title><source>Hum. Mol. Genet.</source><year>2017</year><volume>26</volume><fpage>3466</fpage><lpage>3481</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx227</pub-id><?supplied-pmid 28911198?><pub-id pub-id-type="pmid">28911198</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhoades</surname><given-names>E</given-names></name><name><surname>Ramlall</surname><given-names>TF</given-names></name><name><surname>Webb</surname><given-names>WW</given-names></name><name><surname>Eliezer</surname><given-names>D</given-names></name></person-group><article-title>Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy</article-title><source>Biophys. J.</source><year>2006</year><volume>90</volume><fpage>4692</fpage><lpage>4700</lpage><pub-id pub-id-type="doi">10.1529/biophysj.105.079251</pub-id><?supplied-pmid 16581836?><pub-id pub-id-type="pmid">16581836</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>AJ</given-names></name><name><surname>Selkoe</surname><given-names>D</given-names></name><name><surname>Dettmer</surname><given-names>U</given-names></name></person-group><article-title>A new method for quantitative immunoblotting of endogenous alpha-synuclein</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e81314</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0081314</pub-id><?supplied-pmid 24278419?><pub-id pub-id-type="pmid">24278419</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characterization and identification of dityrosine cross-linked peptides using tandem mass spectrometry</article-title><source>Anal. Chem.</source><year>2017</year><volume>89</volume><fpage>6136</fpage><lpage>6145</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.7b00941</pub-id><?supplied-pmid 28453255?><pub-id pub-id-type="pmid">28453255</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Getoff</surname><given-names>N</given-names></name></person-group><article-title>Pulse radiolysis of aromatic amino acids - state of the art</article-title><source>Amino Acids</source><year>1992</year><volume>2</volume><fpage>195</fpage><lpage>214</lpage><?supplied-pmid 24192899?><pub-id pub-id-type="pmid">24192899</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papagiannakis</surname><given-names>N</given-names></name><etal/></person-group><article-title>Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson&#x02019;s disease</article-title><source>Neurosci. Lett.</source><year>2018</year><volume>672</volume><fpage>145</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2017.11.012</pub-id><?supplied-pmid 29129675?><pub-id pub-id-type="pmid">29129675</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wordehoff</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Opposed effects of dityrosine formation in soluble and aggregated alpha-synuclein on fibril growth</article-title><source>J. Mol. Biol.</source><year>2017</year><volume>429</volume><fpage>3018</fpage><lpage>3030</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2017.09.005</pub-id><?supplied-pmid 28918091?><pub-id pub-id-type="pmid">28918091</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stryer</surname><given-names>L</given-names></name><name><surname>Haugland</surname><given-names>RP</given-names></name></person-group><article-title>Energy transfer: a spectroscopic ruler</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1967</year><volume>58</volume><fpage>719</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1073/pnas.58.2.719</pub-id><?supplied-pmid 5233469?><pub-id pub-id-type="pmid">5233469</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosatto</surname><given-names>L</given-names></name><etal/></person-group><article-title>Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson&#x02019;s disease genetically related mutants</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>16696</fpage><pub-id pub-id-type="doi">10.1038/srep16696</pub-id><?supplied-pmid 26582456?><pub-id pub-id-type="pmid">26582456</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>S</given-names></name><name><surname>Meuvis</surname><given-names>J</given-names></name><name><surname>Hendrix</surname><given-names>J</given-names></name><name><surname>Carl</surname><given-names>SA</given-names></name><name><surname>Engelborghs</surname><given-names>Y</given-names></name></person-group><article-title>Early aggregation steps in alpha-synuclein as measured by FCS and FRET: evidence for a contagious conformational change</article-title><source>Biophys. J.</source><year>2010</year><volume>98</volume><fpage>1302</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2009.12.4290</pub-id><?supplied-pmid 20371330?><pub-id pub-id-type="pmid">20371330</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iljina</surname><given-names>M</given-names></name><etal/></person-group><article-title>Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E1206</fpage><lpage>E1215</lpage><pub-id pub-id-type="doi">10.1073/pnas.1524128113</pub-id><?supplied-pmid 26884195?><pub-id pub-id-type="pmid">26884195</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camacho</surname><given-names>R</given-names></name><name><surname>Tauber</surname><given-names>D</given-names></name><name><surname>Scheblykin</surname><given-names>IG</given-names></name></person-group><article-title>Fluorescence anisotropy reloaded-emerging polarization microscopy methods for assessing chromophores&#x02019; organization and excitation energy transfer in single molecules, particles, films, and beyond</article-title><source>Adv. Mater.</source><year>2019</year><volume>31</volume><fpage>e1805671</fpage><pub-id pub-id-type="doi">10.1002/adma.201805671</pub-id><?supplied-pmid 30721532?><pub-id pub-id-type="pmid">30721532</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamasaki</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Parkinson&#x02019;s disease and multiple system atrophy have distinct alpha-synuclein seed characteristics</article-title><source>J. Biol. Chem.</source><year>2019</year><volume>294</volume><fpage>1045</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.004471</pub-id><?supplied-pmid 30478174?><pub-id pub-id-type="pmid">30478174</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimant</surname><given-names>H</given-names></name><etal/></person-group><article-title>Direct detection of alpha synuclein oligomers in vivo</article-title><source>Acta Neuropathol. Commun.</source><year>2013</year><volume>1</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/2051-5960-1-6</pub-id><?supplied-pmid 24252244?><pub-id pub-id-type="pmid">24252244</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>RF</given-names></name><name><surname>Wade-Martins</surname><given-names>R</given-names></name><name><surname>Alegre-Abarrategui</surname><given-names>J</given-names></name></person-group><article-title>Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson&#x02019;s disease brain</article-title><source>Brain</source><year>2015</year><volume>138</volume><fpage>1642</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1093/brain/awv040</pub-id><?supplied-pmid 25732184?><pub-id pub-id-type="pmid">25732184</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betzig</surname><given-names>E</given-names></name><etal/></person-group><article-title>Imaging intracellular fluorescent proteins at nanometer resolution</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1642</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1126/science.1127344</pub-id><?supplied-pmid 16902090?><pub-id pub-id-type="pmid">16902090</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauvet</surname><given-names>B</given-names></name><etal/></person-group><article-title>alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and <italic>Escherichia coli</italic> exists predominantly as disordered monomer</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>15345</fpage><lpage>15364</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.318949</pub-id><?supplied-pmid 22315227?><pub-id pub-id-type="pmid">22315227</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alderson</surname><given-names>TR</given-names></name><name><surname>Markley</surname><given-names>JL</given-names></name></person-group><article-title>Biophysical characterization of alpha-synuclein and its controversial structure</article-title><source>Intrinsically Disord. Proteins</source><year>2013</year><volume>1</volume><fpage>18</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.4161/idp.26255</pub-id><?supplied-pmid 24634806?><pub-id pub-id-type="pmid">24634806</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eliezer</surname><given-names>D</given-names></name><name><surname>Kutluay</surname><given-names>E</given-names></name><name><surname>Bussell</surname><given-names>R</given-names><suffix>Jr.</suffix></name><name><surname>Browne</surname><given-names>G</given-names></name></person-group><article-title>Conformational properties of alpha-synuclein in its free and lipid-associated states</article-title><source>J. Mol. Biol.</source><year>2001</year><volume>307</volume><fpage>1061</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1006/jmbi.2001.4538</pub-id><?supplied-pmid 11286556?><pub-id pub-id-type="pmid">11286556</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinreb</surname><given-names>PH</given-names></name><name><surname>Zhen</surname><given-names>W</given-names></name><name><surname>Poon</surname><given-names>AW</given-names></name><name><surname>Conway</surname><given-names>KA</given-names></name><name><surname>Lansbury</surname><given-names>PT</given-names><suffix>Jr.</suffix></name></person-group><article-title>NACP, a protein implicated in Alzheimer&#x02019;s disease and learning, is natively unfolded</article-title><source>Biochem</source><year>1996</year><volume>35</volume><fpage>13709</fpage><lpage>13715</lpage><pub-id pub-id-type="doi">10.1021/bi961799n</pub-id><pub-id pub-id-type="pmid">8901511</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araki</surname><given-names>K</given-names></name><etal/></person-group><article-title>A small-angle X-ray scattering study of alpha-synuclein from human red blood cells</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>30473</fpage><pub-id pub-id-type="doi">10.1038/srep30473</pub-id><?supplied-pmid 27469540?><pub-id pub-id-type="pmid">27469540</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dedmon</surname><given-names>MM</given-names></name><name><surname>Lindorff-Larsen</surname><given-names>K</given-names></name><name><surname>Christodoulou</surname><given-names>J</given-names></name><name><surname>Vendruscolo</surname><given-names>M</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name></person-group><article-title>Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations</article-title><source>J. Am. Chem. Soc.</source><year>2005</year><volume>127</volume><fpage>476</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1021/ja044834j</pub-id><?supplied-pmid 15643843?><pub-id pub-id-type="pmid">15643843</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvin</surname><given-names>JE</given-names></name><name><surname>Schuck</surname><given-names>TM</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra</article-title><source>Exp. Neurol.</source><year>2001</year><volume>168</volume><fpage>347</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1006/exnr.2000.7615</pub-id><?supplied-pmid 11259122?><pub-id pub-id-type="pmid">11259122</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fakhree</surname><given-names>MAA</given-names></name><name><surname>Nolten</surname><given-names>IS</given-names></name><name><surname>Blum</surname><given-names>C</given-names></name><name><surname>Claessens</surname><given-names>M</given-names></name></person-group><article-title>Different conformational subensembles of the intrinsically disordered protein alpha-synuclein in cells</article-title><source>J. Phys. Chem. Lett.</source><year>2018</year><volume>9</volume><fpage>1249</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1021/acs.jpclett.8b00092</pub-id><?supplied-pmid 29474083?><pub-id pub-id-type="pmid">29474083</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrivastava</surname><given-names>AN</given-names></name><name><surname>Aperia</surname><given-names>A</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Triller</surname><given-names>A</given-names></name></person-group><article-title>Physico-pathologic mechanisms involved in neurodegeneration: misfolded protein-plasma membrane interactions</article-title><source>Neuron</source><year>2017</year><volume>95</volume><fpage>33</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.05.026</pub-id><?supplied-pmid 28683268?><pub-id pub-id-type="pmid">28683268</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dikiy</surname><given-names>I</given-names></name><etal/></person-group><article-title>Semisynthetic and in vitro phosphorylation of alpha-synuclein at Y39 promotes functional partly helical membrane-bound states resembling those induced by PD mutations</article-title><source>ACS Chem. Biol.</source><year>2016</year><volume>11</volume><fpage>2428</fpage><lpage>2437</lpage><pub-id pub-id-type="doi">10.1021/acschembio.6b00539</pub-id><?supplied-pmid 27356045?><pub-id pub-id-type="pmid">27356045</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>VL</given-names></name><name><surname>Ramlall</surname><given-names>TF</given-names></name><name><surname>Rospigliosi</surname><given-names>CC</given-names></name><name><surname>Webb</surname><given-names>WW</given-names></name><name><surname>Eliezer</surname><given-names>D</given-names></name></person-group><article-title>Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>18850</fpage><lpage>18855</lpage><pub-id pub-id-type="doi">10.1073/pnas.1012336107</pub-id><?supplied-pmid 20947801?><pub-id pub-id-type="pmid">20947801</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal alpha-synuclein preformed fibrils</article-title><source>Neurobiol. Dis.</source><year>2019</year><volume>130</volume><fpage>104525</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2019.104525</pub-id><?supplied-pmid 31276792?><pub-id pub-id-type="pmid">31276792</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>A</given-names></name><name><surname>Claessens</surname><given-names>M</given-names></name></person-group><article-title>Disruptive membrane interactions of alpha-synuclein aggregates. <italic>Biochimica et biophysica acta</italic></article-title><source>Proteins Proteom.</source><year>2019</year><volume>1867</volume><fpage>468</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2018.10.006</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakabayashi</surname><given-names>K</given-names></name><name><surname>Tanji</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>F</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name></person-group><article-title>The Lewy body in Parkinson&#x02019;s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates</article-title><source>Neuropathol</source><year>2007</year><volume>27</volume><fpage>494</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1789.2007.00803.x</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakabayashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>The Lewy body in Parkinson&#x02019;s disease and related neurodegenerative disorders</article-title><source>Mol. Neurobiol.</source><year>2013</year><volume>47</volume><fpage>495</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1007/s12035-012-8280-y</pub-id><?supplied-pmid 22622968?><pub-id pub-id-type="pmid">22622968</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Relationships between Lewy bodies and pale bodies in Parkinson&#x02019;s disease</article-title><source>Acta Neuropathol.</source><year>1992</year><volume>83</volume><fpage>525</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1007/BF00310030</pub-id><?supplied-pmid 1320323?><pub-id pub-id-type="pmid">1320323</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Tortosa</surname><given-names>E</given-names></name><name><surname>Newell</surname><given-names>K</given-names></name><name><surname>Irizarry</surname><given-names>MC</given-names></name><name><surname>Sanders</surname><given-names>JL</given-names></name><name><surname>Hyman</surname><given-names>B</given-names></name></person-group><article-title>T. alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining</article-title><source>Acta Neuropathol.</source><year>2000</year><volume>99</volume><fpage>352</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1007/s004010051135</pub-id><?supplied-pmid 10787032?><pub-id pub-id-type="pmid">10787032</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuusisto</surname><given-names>E</given-names></name><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name></person-group><article-title>Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62</article-title><source>J. Neuropathol. Exp. Neurol.</source><year>2003</year><volume>62</volume><fpage>1241</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1093/jnen/62.12.1241</pub-id><?supplied-pmid 14692700?><pub-id pub-id-type="pmid">14692700</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Pale neurites, premature alpha-synuclein aggregates with centripetal extension from axon collaterals</article-title><source>Brain Pathol.</source><year>2012</year><volume>22</volume><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2011.00509.x</pub-id><?supplied-pmid 21672073?><pub-id pub-id-type="pmid">21672073</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakabayashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy</article-title><source>Acta Neuropathol.</source><year>1998</year><volume>96</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1007/s004010050918</pub-id><?supplied-pmid 9829807?><pub-id pub-id-type="pmid">9829807</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soper</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Alpha-synuclein-induced aggregation of cytoplasmic vesicles in <italic>Saccharomyces cerevisiae</italic></article-title><source>Mol. Biol. cell</source><year>2008</year><volume>19</volume><fpage>1093</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1091/mbc.e07-08-0827</pub-id><?supplied-pmid 18172022?><pub-id pub-id-type="pmid">18172022</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Issidorides</surname><given-names>MR</given-names></name><name><surname>Panayotacopoulou</surname><given-names>MT</given-names></name><name><surname>Tiniacos</surname><given-names>G</given-names></name></person-group><article-title>Similarities between neuronal Lewy bodies in parkinsonism and hepatic Mallory bodies in alcoholism</article-title><source>Pathol. Res. Pract.</source><year>1990</year><volume>186</volume><fpage>473</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/S0344-0338(11)80466-8</pub-id><?supplied-pmid 2247376?><pub-id pub-id-type="pmid">2247376</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gai</surname><given-names>WP</given-names></name><etal/></person-group><article-title>In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies</article-title><source>Exp. Neurol.</source><year>2000</year><volume>166</volume><fpage>324</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1006/exnr.2000.7527</pub-id><?supplied-pmid 11085897?><pub-id pub-id-type="pmid">11085897</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahmoradian</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Lewy pathology in Parkinson&#x02019;s disease consists of crowded organelles and lipid membranes</article-title><source>Nat. Neurosci.</source><year>2019</year><volume>22</volume><fpage>1099</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0423-2</pub-id><?supplied-pmid 31235907?><pub-id pub-id-type="pmid">31235907</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thelen</surname><given-names>AM</given-names></name><name><surname>Zoncu</surname><given-names>R</given-names></name></person-group><article-title>Emerging roles for the lysosome in lipid metabolism</article-title><source>Trends Cell Biol.</source><year>2017</year><volume>27</volume><fpage>833</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2017.07.006</pub-id><?supplied-pmid 28838620?><pub-id pub-id-type="pmid">28838620</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunkle</surname><given-names>BW</given-names></name><etal/></person-group><article-title>Genetic meta-analysis of diagnosed Alzheimer&#x02019;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing</article-title><source>Nat. Genet.</source><year>2019</year><volume>51</volume><fpage>414</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0358-2</pub-id><?supplied-pmid 30820047?><pub-id pub-id-type="pmid">30820047</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>D</given-names></name><etal/></person-group><article-title>A meta-analysis of genome-wide association studies identifies 17 new Parkinson&#x02019;s disease risk loci</article-title><source>Nat. Genet.</source><year>2017</year><volume>49</volume><fpage>1511</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1038/ng.3955</pub-id><?supplied-pmid 28892059?><pub-id pub-id-type="pmid">28892059</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansen</surname><given-names>KK</given-names></name><name><surname>Torp</surname><given-names>SH</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Gustavsson</surname><given-names>EK</given-names></name><name><surname>Aasly</surname><given-names>JO</given-names></name></person-group><article-title>A case of Parkinson&#x02019;s disease with no Lewy body pathology due to a homozygous exon deletion in Parkin</article-title><source>Case Rep. Neurol. Med.</source><year>2018</year><volume>2018</volume><fpage>6838965</fpage><?supplied-pmid 30050705?><pub-id pub-id-type="pmid">30050705</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haberkant</surname><given-names>P</given-names></name><name><surname>Holthuis</surname><given-names>JC</given-names></name></person-group><article-title>Fat &#x00026; fabulous: bifunctional lipids in the spotlight</article-title><source>Biochim. Biophys. Acta</source><year>2014</year><volume>1841</volume><fpage>1022</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2014.01.003</pub-id><?supplied-pmid 24440797?><pub-id pub-id-type="pmid">24440797</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoglinger</surname><given-names>D</given-names></name><etal/></person-group><article-title>Trifunctional lipid probes for comprehensive studies of single lipid species in living cells</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>1566</fpage><lpage>1571</lpage><pub-id pub-id-type="doi">10.1073/pnas.1611096114</pub-id><?supplied-pmid 28154130?><pub-id pub-id-type="pmid">28154130</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zunke</surname><given-names>F</given-names></name><etal/></person-group><article-title>Reversible conformational conversion of alpha-synuclein into toxic assemblies by glucosylceramide</article-title><source>Neuron</source><year>2018</year><volume>97</volume><fpage>92</fpage><lpage>107 e110</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.12.012</pub-id><?supplied-pmid 29290548?><pub-id pub-id-type="pmid">29290548</pub-id></element-citation></ref></ref-list></back></article>